Your browser doesn't support javascript.
loading
Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer.
Kim, Yoon-Jae; Sung, Daeil; Oh, Eunhye; Cho, Youngkwan; Cho, Tae-Min; Farrand, Lee; Seo, Jae Hong; Kim, Ji Young.
Affiliation
  • Kim YJ; Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul 152-703, Republic of Korea; Department of Biomedical Research Center and Rare Diseases Institute, Korea University Guro Hospital, Korea University, Seoul 152-703, Republic of
  • Sung D; Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul 152-703, Republic of Korea; Brain Korea 21 Program for Biomedicine Science, Korea University College of Medicine, Korea University, Seoul 152-703, Republic of Korea.
  • Oh E; Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul 152-703, Republic of Korea; Brain Korea 21 Program for Biomedicine Science, Korea University College of Medicine, Korea University, Seoul 152-703, Republic of Korea.
  • Cho Y; Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul 152-703, Republic of Korea; Brain Korea 21 Program for Biomedicine Science, Korea University College of Medicine, Korea University, Seoul 152-703, Republic of Korea.
  • Cho TM; Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul 152-703, Republic of Korea; Brain Korea 21 Program for Biomedicine Science, Korea University College of Medicine, Korea University, Seoul 152-703, Republic of Korea.
  • Farrand L; Medvet Science, 65 Hardys Rd, Underdale, Adelaide, Australia.
  • Seo JH; Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul 152-703, Republic of Korea; Brain Korea 21 Program for Biomedicine Science, Korea University College of Medicine, Korea University, Seoul 152-703, Republic of Korea. Electroni
  • Kim JY; Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul 152-703, Republic of Korea; Brain Korea 21 Program for Biomedicine Science, Korea University College of Medicine, Korea University, Seoul 152-703, Republic of Korea. Electroni
Cancer Lett ; 412: 118-130, 2018 01 01.
Article in En | MEDLINE | ID: mdl-29080749
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplastic Stem Cells / Breast Neoplasms / Signal Transduction / Receptor, ErbB-2 / Trastuzumab / Antineoplastic Agents, Immunological / Mebendazole Limits: Animals / Female / Humans Language: En Journal: Cancer Lett Year: 2018 Document type: Article Country of publication: Ireland
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplastic Stem Cells / Breast Neoplasms / Signal Transduction / Receptor, ErbB-2 / Trastuzumab / Antineoplastic Agents, Immunological / Mebendazole Limits: Animals / Female / Humans Language: En Journal: Cancer Lett Year: 2018 Document type: Article Country of publication: Ireland